GlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, to a new bioscience cluster that it says could become one of the largest in Europe.

It will allow swift transport links to GSK's main R&D campus in Stevenage – where the company is also developing a new bioscience cluster – and will also be close to its artificial ...

The GSK Stevenage STEM committee is hosting our 4-day on-site work experience again this year. *Monday 28th July to Thursday 31st July 2025* THE APPLICATION PROCESS IS NOW OPEN! GSK's ...

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition with poor survival times. We previously published a genome-wide meta-analysis of IPF risk across three studies with independent ...

GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, U.K.

GSK plc GSK on Wednesday agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Under the agreement, GSK will pay up to $2 billion in total cash consideration. This includes $1 ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...

GSK (NYSE:GSK) reported Q1 2025 results on Wednesday, narrowly beating analysts’ estimates as the British drugmaker’s Specialty Medicines business offset weakness in its Vaccine and General ...